Austrian biotech Marinomed said sales of its virus-blocking compound Carragelose had slumped to pre-pandemic levels as a three-year period of elevated demand came to an end.
Marinomed Sees Sales of Virus-Blocking Nasal Spray Drop To Pre-Pandemic Levels
A "pandemic overhang" is impacting sales of Marinomed's virus-blocking nasal spray platform, Carragelose, which remains under strategic review by the company.
